FIELD: biotechnology.
SUBSTANCE: present invention relates to polyspecific antibodies and can be used in medicine. Invention discloses novel proteins which specifically bind to the NKG2D receptor, CD16 and the tumour-specific trophoblast cell surface antigen (TROP2).
EFFECT: invention can be used in medical practice as a therapeutic agent in the treatment of a number of malignant neoplasms, for example, gastrointestinal cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer and breast cancer.
25 cl, 37 dwg, 14 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| MODIFIED Α1-Α2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND TO NON-NATURAL NKG2D RECEPTORS | 2019 |
|
RU2815278C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
